European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Kyle LaHucik

Senior Reporter

Germany-based investor Earlybird Health has closed its second healthcare-focused fund and has already deployed some of it in biopharma and medtech companies, with one exit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

CBER's deputy director departs as staff shakeup continues

Medicare spending on common diabetes drugs skyrocketed, HHS inspector general finds

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

How AI can address ongoing challenges in the life sciences industry

Eu­ro­pean in­vestor Early­bird Health clos­es $185M fund to back 12 to 15 com­pa­nies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Medicare spend­ing on com­mon di­a­betes drugs sky­rock­et­ed, HHS in­spec­tor gen­er­al finds

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

CBER's deputy director departs as staff shakeup continues

Medicare spending on common diabetes drugs skyrocketed, HHS inspector general finds

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

How AI can address ongoing challenges in the life sciences industry